Vitamin E therapy in patients with NASH
Masashi Yoneda, Takenao Hasegawa, Kimihide Nakamura, Masasya Tamano, Toru Kono, Akira Terano – 30 January 2004
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy
Debbie L. Shawcross, Nathan A. Davies, Rajeshwar P. Mookerjee, Peter C. Hayes, Roger Williams, Alistair Lee, Rajiv Jalan – 30 January 2004 – There is increasing evidence that terlipressin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use in patients with acute liver failure (ALF) in whom hepatorenal syndrome is common. Although terlipressin produces systemic vasoconstriction, it produces cerebral vasodilatation and may increase cerebral blood flow (CBF). Increased CBF contributes to intracranial hypertension in patients with ALF.
Detection and identification of tumor‐associated protein variants in human hepatocellular carcinomas
Evelyn Zeindl‐Eberhart, Sibylle Haraida, Sibylle Liebmann, Peter Roman Jungblut, Stephanie Lamer, Doris Mayer, Gundula Jäger, Stephen Chung, Hartmut Manfred Rabes – 30 January 2004 – The proteomic approach is a valuable tool to detect and identify proteins that are associated with cancer. In previous investigations on experimentally induced rat hepatomas, we detected aldose reductase‐like protein (ARLP) as a highly significant marker protein. Our present study was intended to look for the presence of similar tumor‐associated marker proteins on human hepatocellular carcinomas (HCC).
Hepatology highlights
Neil Kaplowitz – 30 January 2004
Prognostic prediction in HCC: Did anybody expect it to be easy?
Jordi Bruix, Josep M. Llovet – 30 January 2004
Surgical treatment of hepatocellular carcinoma: Similar long‐term results despite geographic variations
Timothy M. Pawlik, Nestor F. Esnaola, Jean‐Nicolas Vauthey – 30 January 2004 – Recently, the International Cooperative Study Group for hepatocellular carcinoma (HCC) proposed a new staging based on data from multiple centers across the world. The new TNM staging has been shown to be more accurate in the prognostic classification of patients after resection for HCC. This staging is the basis for the new TNM for HCC approved by the AJCC (American Joint Committee on Cancer) and UICC (Union Internationale Contre le Cancer).
Multimodal image‐guided tailored therapy of early and intermediate hepatocellular carcinoma: Long‐term survival in the experience of a single radiologic referral center
Tito Livraghi, Franca Meloni, Alberto Morabito, Claudio Vettori – 30 January 2004 – The best treatment policy for some patients with hepatocellular carcinoma (HCC) and compensated cirrhosis is still controversial. The aim of this study was to evaluate the long‐term survival and related prognostic factors of patients with early and intermediate HCC (Liver Unit of Barcelona classification) treated in a radiologic referral center by a multimodal image‐guided tailored therapy (MIGTT), applied over time, choosing the procedure patient by patient according to the presentation of the disease.
Steroid‐free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy
John G. O'Grady – 30 January 2004
Reply:
Craig McClain, Daniel Hill, Marcello Kugelmas – 30 January 2004
Structured treatment interruption in patients with alveolar echinococcosis
Stefan Reuter, Andreas Buck, Burkhard Manfras, Wolfgang Kratzer, Hanns Martin Seitz, Kassa Darge, Sven Norbert Reske, Peter Kern – 30 January 2004 – In human alveolar echinococcosis (AE), benzimidazoles are given throughout life because they are only parasitostatic. It has been a longstanding goal to limit treatment, and recent reports suggest that, in selected cases, benzimidazoles may be parasitocidal. Previously, we showed that positron –emission tomography (PET) using [18F]fluoro‐deoxyglucose discriminates active from inactive lesions in AE.